Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Comparison of CJ-30056 vs Atorvastatin and Metformin XR
NCT02185066Phase 1Completed
- Sponsor
- HK inno.N Corporation
- Start
- Jul 2014
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of atorvastatin + metformin in type 2 diabetes mellitus (T2DM) and hypercholesterolemia (2 arms), sponsored by HK inno.N Corporation. Primary endpoints: Maximum plasma concentration of Atorvastatin at 36 hours, Maximum plasma concentration of Metformin at 24 hours and 2 more. Started Jul 2014; status: completed.
02
Drugs
atorvastatin + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)hypercholesterolemia
Beyond the preview
Go deeper on NCT02185066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02185066.